Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Last Close
May 24 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-3.48 Insider Own0.30% Shs Outstand150.41M Perf Week-2.42%
Market Cap2.79B Forward P/E- EPS next Y-1.03 Insider Trans0.00% Shs Float150.21M Perf Month2.26%
Income-500.55M PEG- EPS next Q-0.54 Inst Own7.43% Short Float1.18% Perf Quarter4.80%
Sales220.60M P/S12.66 EPS this Y-11.13% Inst Trans5.79% Short Ratio4.09 Perf Half Y307.47%
Book/sh-1.88 P/B- EPS next Y38.22% ROA-22.56% Short Interest1.77M Perf Year195.69%
Cash/sh4.52 P/C4.10 EPS next 5Y- ROE-185.77% 52W Range4.18 - 19.50 Perf YTD87.27%
Dividend Est.- P/FCF- EPS past 5Y-23.10% ROI- 52W High-4.92% Beta1.18
Dividend TTM- Quick Ratio1.38 Sales past 5Y67.37% Gross Margin75.93% 52W Low343.01% ATR (14)0.29
Dividend Ex-Date- Current Ratio1.38 EPS Y/Y TTM-453.93% Oper. Margin-219.08% RSI (14)56.74 Volatility1.12% 1.47%
Employees564 Debt/Eq- Sales Y/Y TTM-28.78% Profit Margin-226.90% Recom3.00 Target Price18.28
Option/ShortYes / Yes LT Debt/Eq- EPS Q/Q-551.32% Payout- Rel Volume0.12 Prev Close18.31
Sales Surprise-49.94% EPS Surprise-638.62% Sales Q/Q-55.30% EarningsApr 29 AMC Avg Volume434.05K Price18.54
SMA202.21% SMA502.46% SMA20057.54% Trades Volume53,527 Change1.26%
Date Action Analyst Rating Change Price Target Change
Mar-14-24Downgrade Wells Fargo Overweight → Equal Weight
Jan-16-24Downgrade Morgan Stanley Overweight → Equal-Weight $9.20 → $10.40
Oct-13-23Upgrade Morgan Stanley Underweight → Overweight $3.70 → $9.20
Sep-15-23Upgrade Goldman Sell → Neutral $3.50 → $9.25
Jul-17-23Upgrade Deutsche Bank Sell → Hold
Jun-16-23Upgrade JP Morgan Underweight → Overweight $3.30 → $10
Jun-16-23Initiated Wells Fargo Overweight $17
May-31-23Initiated UBS Buy
Jan-06-23Downgrade Morgan Stanley Equal-Weight → Underweight
Dec-16-22Downgrade Goldman Neutral → Sell
May-17-24 05:51AM
May-09-24 10:46AM
Apr-30-24 07:52AM
Apr-29-24 04:01PM
Apr-24-24 11:00AM
10:12AM Loading…
Apr-23-24 10:12AM
Apr-12-24 06:26AM
Apr-11-24 09:00AM
Apr-03-24 08:48AM
Mar-30-24 03:52PM
Mar-22-24 02:50AM
Mar-15-24 10:37AM
Mar-13-24 04:02PM
Mar-11-24 12:44PM
Mar-07-24 04:15PM
02:56AM Loading…
Mar-05-24 02:56AM
Mar-04-24 12:00PM
Feb-16-24 03:55AM
Feb-15-24 12:00PM
Feb-06-24 10:29AM
Feb-05-24 05:44PM
Jan-30-24 03:15AM
Jan-08-24 02:20AM
Dec-10-23 07:31PM
09:09AM Loading…
Nov-21-23 09:09AM
Nov-20-23 04:50PM
Nov-17-23 09:59AM
Nov-15-23 04:01PM
Nov-09-23 04:20PM
Nov-02-23 09:45AM
Oct-25-23 05:10AM
Sep-15-23 09:32AM
Sep-12-23 04:20PM
Aug-09-23 04:01PM
Jun-26-23 04:00PM
May-03-23 04:01PM
Apr-27-23 04:20PM
Apr-17-23 03:32AM
Apr-16-23 03:01PM
Mar-19-23 11:15PM
Mar-15-23 04:03PM
Mar-09-23 04:20PM
Mar-02-23 04:00AM
Jan-09-23 01:20AM
Jan-05-23 06:00AM
Dec-07-22 09:48AM
Nov-28-22 04:30PM
Nov-19-22 01:45AM
Nov-16-22 04:01PM
Nov-14-22 04:11PM
Nov-10-22 04:30PM
Nov-08-22 12:45AM
Nov-03-22 09:25AM
Oct-28-22 11:14AM
Oct-27-22 04:20PM
Oct-21-22 06:00AM
Sep-29-22 09:21AM
Aug-06-22 02:00PM
Aug-03-22 04:01PM
Jul-28-22 04:20PM
Jul-26-22 05:40AM
Jun-15-22 08:30AM
Jun-14-22 04:57PM
Jun-10-22 03:15AM
May-18-22 08:05PM
May-12-22 10:45AM
May-05-22 08:30PM
May-04-22 04:01PM
Apr-28-22 04:45PM
Apr-12-22 09:55AM
Mar-23-22 07:05AM
Mar-22-22 04:45PM
Mar-16-22 04:07PM
Mar-15-22 04:40PM
Mar-10-22 04:35PM
Jan-24-22 04:20PM
Jan-18-22 01:00AM
Jan-10-22 02:20AM
Dec-12-21 09:00AM
Dec-11-21 12:00PM
MorphoSys AG is a biopharmaceutical company, which engages in the development and commercialization of cancer therapeutics. Its clinical programs focus on Pelabresib and Tulmimetostat. The company was founded by Andreas Pluckthun and Simon E. Moroney in July 1992 and is headquartered in Planegg, Germany.